ABSTRACT
BACKGROUND: By identifying occupational problems, job-related therapies may be included in rehabilitation at an early stage, increasing the return-to-work rate. The aim of the present study was to examine whether occupational problems that were identified were associated with the employment status six months after inpatient rehabilitation. METHODS: A total of 122 neurological patients undergoing neurological inpatient rehabilitation at the BDH-Clinic Hessisch Oldendorf were retrospectively analysed using clinical routine data from the database of the clinic. Occupational problems were identified with the help of a self-assessment (Wuerzburg Screening [WS]) and an ICF-compliant medical assessment (d850) at the beginning of neurological rehabilitation. In addition, data about the employment status six months after rehabilitation were collected. RESULTS: While the BPL identified in the WS was associated with the employment status at the time of follow-up (r=-0.288; p=.007), there was no relationship between the medical assessment of occupational impairment and the employment status. In binary logistic regression models for predicting the employment status, the duration of the incapacity to work, age, gender and an interdisciplinary assessment at the end of rehabilitation proved to be predictors for the employment status. CONCLUSION: Occupational problems are associated with occupational reintegration six months after discharge from neurological inpatient rehabilitation. Since occupational problems are taken into account in the treatment planning, the impact on the return to work rate may be underestimated in the current study.
Subject(s)
Inpatients , Neurological Rehabilitation , Employment , Humans , Retrospective Studies , Return to WorkABSTRACT
BACKGROUND: High-density lipoprotein (HDL)-raising therapies are currently under intense evaluation, but the effects of HDL may be highly heterogeneous. We therefore compared the endothelial effects of HDL from healthy subjects and from patients with type 2 diabetes mellitus and low HDL (meeting the criteria for metabolic syndrome), who are frequently considered for HDL-raising therapies. Moreover, in diabetic patients, we examined the impact of extended-release (ER) niacin therapy on the endothelial effects of HDL. METHODS AND RESULTS: HDL was isolated from healthy subjects (n=10) and patients with type 2 diabetes (n=33) by sequential ultracentrifugation. Effects of HDL on endothelial nitric oxide and superoxide production were characterized by electron spin resonance spectroscopy analysis. Effects of HDL on endothelium-dependent vasodilation and early endothelial progenitor cell-mediated endothelial repair were examined. Patients with diabetes were randomized to a 3-month therapy with ER niacin (1500 mg/d) or placebo, and endothelial effects of HDL were characterized. HDL from healthy subjects stimulated endothelial nitric oxide production, reduced endothelial oxidant stress, and improved endothelium-dependent vasodilation and early endothelial progenitor cell-mediated endothelial repair. In contrast, these beneficial endothelial effects of HDL were not observed in HDL from diabetic patients, which suggests markedly impaired endothelial-protective properties of HDL. ER niacin therapy improved the capacity of HDL to stimulate endothelial nitric oxide, to reduce superoxide production, and to promote endothelial progenitor cell-mediated endothelial repair. Further measurements suggested increased lipid oxidation of HDL in diabetic patients, and a reduction after ER niacin therapy. CONCLUSIONS: HDL from patients with type 2 diabetes mellitus and metabolic syndrome has substantially impaired endothelial-protective effects compared with HDL from healthy subjects. ER niacin therapy not only increases HDL plasma levels but markedly improves endothelial-protective functions of HDL in these patients, which is potentially more important. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov. Identifier: NCT00346970.
